Last reviewed · How we verify
Single Agent IV Antibiotic Therapy - MSSA
Single-agent intravenous antibiotic therapy targets and kills methicillin-susceptible Staphylococcus aureus (MSSA) by inhibiting bacterial cell wall synthesis.
Single-agent intravenous antibiotic therapy targets and kills methicillin-susceptible Staphylococcus aureus (MSSA) by inhibiting bacterial cell wall synthesis. Used for Methicillin-susceptible Staphylococcus aureus (MSSA) infections (bacteremia, endocarditis, osteomyelitis, pneumonia, skin/soft tissue infections).
At a glance
| Generic name | Single Agent IV Antibiotic Therapy - MSSA |
|---|---|
| Also known as | cefazolin, oxacillin, nafcillin, rifampin |
| Sponsor | West Virginia University |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This represents a clinical protocol or treatment approach rather than a single novel drug entity. It typically involves beta-lactam antibiotics (such as nafcillin, oxacillin, or cefazolin) administered intravenously as monotherapy against MSSA infections. These agents work by binding to penicillin-binding proteins and disrupting peptidoglycan cross-linking in the bacterial cell wall, leading to cell lysis and death.
Approved indications
- Methicillin-susceptible Staphylococcus aureus (MSSA) infections (bacteremia, endocarditis, osteomyelitis, pneumonia, skin/soft tissue infections)
Common side effects
- Hypersensitivity/allergic reaction
- Phlebitis at infusion site
- Nausea/vomiting
- Diarrhea
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: